Entrada Therapeutics Beheer
Beheer criteriumcontroles 3/4
De CEO Entrada Therapeutics is Dipal Doshi, benoemd in Aug2017, heeft een ambtstermijn van 8.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.84M, bestaande uit 16.5% salaris en 83.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.57% van de aandelen van het bedrijf, ter waarde $ 1.30M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.8 jaar en 5 jaar.
Belangrijke informatie
Dipal Doshi
Algemeen directeur
US$3.8m
Totale compensatie
| Percentage CEO-salaris | 16.55% |
| Dienstverband CEO | 8.8yrs |
| Eigendom CEO | 0.6% |
| Management gemiddelde ambtstermijn | 4.8yrs |
| Gemiddelde ambtstermijn bestuur | 5yrs |
Recente managementupdates
Recent updates
DMD Franchise And Ocular Pipeline Will Create Multiple Long Term Genetic Medicine Opportunities
Catalysts About Entrada Therapeutics Entrada Therapeutics is a clinical stage biopharma company developing proprietary genetic medicines for high unmet need diseases, with a focus on neuromuscular and ocular disorders. What are the underlying business or industry changes driving this perspective?Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Fly 26% But Investors Aren't Buying For Growth
Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) shares have continued their recent momentum with a 26% gain in the last...Entrada Therapeutics: Soft Q3 Earnings, But Builds Momentum Toward 2026 Readouts
Summary Entrada Therapeutics reported a 3Q25 GAAP EPS loss of –$1.06 and revenue of $1.6 million, reflecting declining collaboration income. TRDA is heavily investing in its Duchenne muscular dystrophy pipeline, with multiple early-stage clinical programs converging on key data readouts in 2026. Despite widening losses, TRDA maintains a strong cash position of $326.8 million, sufficient to fund operations through 3Q27 and support ongoing R&D. The stock trades at a deep valuation discount due to its large cash balance, but faces amplified risk from clustered 2026 clinical catalysts. Read the full article on Seeking AlphaEntrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 32% But Its Business Still Trails The Industry
Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) shares have had a really impressive month, gaining 32% after a shaky period...Entrada Therapeutics, Inc. (NASDAQ:TRDA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) just released its latest second-quarter report and things are not looking...Lacklustre Performance Is Driving Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) 27% Price Drop
To the annoyance of some shareholders, Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) shares are down a considerable 27% in...Results: Entrada Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
As you might know, Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) just kicked off its latest yearly results with some very...Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside
Summary Entrada Therapeutics addresses intracellular drug delivery challenges with its Endosomal Escape Vehicle platform, positioning itself uniquely in the biotech sector. Strong financials with $449.3 million in reserves and strategic partnerships extend Entrada's runway into 2027, reducing near-term financing risks. ENTR-601-44, targeting Duchenne muscular dystrophy, is entering critical trials, with potential to validate the platform and drive significant market share. Despite scientific and execution risks, successful trials could elevate Entrada's valuation and establish it as a leader in oligonucleotide-based therapies. Read the full article on Seeking AlphaThe Market Doesn't Like What It Sees From Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Revenues Yet As Shares Tumble 26%
Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) shares have had a horrible month, losing 26% after a relatively good period...There Is A Reason Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Price Is Undemanding
Entrada Therapeutics, Inc.'s ( NASDAQ:TRDA ) price-to-sales (or "P/S") ratio of 2.6x might make it look like a strong...Analysts' Revenue Estimates For Entrada Therapeutics, Inc. (NASDAQ:TRDA) Are Surging Higher
Celebrations may be in order for Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) shareholders, with the analysts delivering...Entrada Therapeutics: A Complicated Tale
Summary Entrada Therapeutics' stock has dropped significantly due to FDA holds on two IND applications, but recent insider buying suggests potential upside. The company's EEV platform aims to target malady-inducing dysfunction inside cells with high proficiency, potentially revolutionizing treatment across various diseases. Despite ongoing FDA issues, analysts remain optimistic about Entrada's prospects, with a well-padded balance sheet and potential for future collaborations. An analysis around Entrada Therapeutics stock follows in the paragraphs below. Read the full article on Seeking AlphaEntrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry
The Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) share price has done very well over the last month, posting an excellent...These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts
One thing we could say about the analysts on Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) - they aren't optimistic...This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year
Shareholders in Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) may be thrilled to learn that the analysts have just...Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)
Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) shareholders will have a reason to smile today, with the analysts making...Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts
Investors in Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) had a good week, as its shares rose 3.1% to close at US$12.50...Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Entrada Therapeutics GAAP EPS of -$0.74 misses by $0.02
Entrada Therapeutics press release (NASDAQ:TRDA): Q2 GAAP EPS of -$0.74 misses by $0.02. Cash, cash equivalents and marketable securities were $244.3 million as of June 30, 2022, compared to $291.1 million as of December 31, 2021.We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$166m |
| Dec 31 2025 | US$4m | US$635k | -US$144m |
| Sep 30 2025 | n/a | n/a | -US$103m |
| Jun 30 2025 | n/a | n/a | -US$73m |
| Mar 31 2025 | n/a | n/a | US$25m |
| Dec 31 2024 | US$4m | US$610k | US$66m |
| Sep 30 2024 | n/a | n/a | US$55m |
| Jun 30 2024 | n/a | n/a | US$104m |
| Mar 31 2024 | n/a | n/a | US$23m |
| Dec 31 2023 | US$4m | US$585k | -US$7m |
| Sep 30 2023 | n/a | n/a | -US$22m |
| Jun 30 2023 | n/a | n/a | -US$82m |
| Mar 31 2023 | n/a | n/a | -US$80m |
| Dec 31 2022 | US$3m | US$565k | -US$95m |
| Sep 30 2022 | n/a | n/a | -US$88m |
| Jun 30 2022 | n/a | n/a | -US$78m |
| Mar 31 2022 | n/a | n/a | -US$64m |
| Dec 31 2021 | US$6m | US$425k | -US$51m |
| Sep 30 2021 | n/a | n/a | -US$41m |
| Jun 30 2021 | n/a | n/a | -US$34m |
| Mar 31 2021 | n/a | n/a | -US$29m |
| Dec 31 2020 | US$906k | US$385k | -US$27m |
Compensatie versus markt: De totale vergoeding ($USD 3.84M ) Dipal } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.72M ).
Compensatie versus inkomsten: De vergoeding van Dipal is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Dipal Doshi (49 yo)
Mr. Dipal Doshi is Independent Director of Azenta, Inc. from January 30, 2025. Mr. Doshi serves as Director of The Children's Health Fund. He serves as Director of Ashibio, Inc since September 2024.Mr. Do...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 8.8yrs | US$3.84m | 0.57% $ 1.3m | |
| President & COO | 6.5yrs | US$2.22m | 0.55% $ 1.3m | |
| President of Research & Development | 2.3yrs | US$2.25m | 0.30% $ 673.1k | |
| CFO & Treasurer | 5.5yrs | geen gegevens | 0.042% $ 95.5k | |
| General Counsel | 6.1yrs | geen gegevens | geen gegevens | |
| Senior Vice President of People | 4.8yrs | geen gegevens | geen gegevens | |
| Chief Corporate Affairs Officer | 3.8yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Regulatory Affairs | 2.3yrs | geen gegevens | geen gegevens | |
| Head of Information Technology | 1.3yrs | geen gegevens | geen gegevens |
Ervaren management: Het managementteam van TRDA wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 8.8yrs | US$3.84m | 0.57% $ 1.3m | |
| Director | 5.4yrs | US$144.39k | 0.36% $ 816.1k | |
| Industry Leader & Independent Director | 5yrs | US$167.43k | 0% $ 0 | |
| Independent Chairman of the Board | 9.6yrs | US$202.60k | 0% $ 0 | |
| Independent Director | 3.1yrs | US$150.68k | 0% $ 0 | |
| Independent Director | less than a year | US$230.93k | 0% $ 0 | |
| Independent Director | 2.7yrs | US$157.55k | 0% $ 0 |
Ervaren bestuur: De raad van bestuur van TRDA wordt beschouwd als ervaren (gemiddelde ambtstermijn 5 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/22 23:07 |
| Aandelenkoers aan het einde van de dag | 2026/05/22 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Entrada Therapeutics, Inc. wordt gevolgd door 10 analisten. 8 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Ioannis Souroutzidis | Cantor Fitzgerald & Co. |
| Paul Choi | Goldman Sachs |
| Debjit Chattopadhyay | Guggenheim Securities, LLC |